# Theophylline Treatment for Pseudohypoparathyroidism

> **NCT03029429** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Vanderbilt University Medical Center** · enrollment: 29 (actual)

## Conditions studied

- Pseudohypoparathyroidism
- Albright Hereditary Osteodystrophy

## Interventions

- **DRUG:** Theophylline
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03029429
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-09-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03029429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03029429, "Theophylline Treatment for Pseudohypoparathyroidism". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03029429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*